Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece

被引：0
|
作者：
Theodoros V. Giannouchos
Dimos-Dimitrios Mitsikostas
Robert L. Ohsfeldt
Athanassios Vozikis
Paraskevi Koufopoulou
机构：
[1] Texas A&M University,Department of Health Policy and Management, School of Public Health
[2] Texas A&M University,Population Informatics Lab
[3] National and Kapodistrian University of Athens,First Neurology Department, Aeginition Hospital, School of Medicine
[4] University of Piraeus,Laboratory of Health Economics and Management, Economics Department
[5] KAT General Hospital of Attica,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：979 / 990
页数：11
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece
    Giannouchos, Theodoros V.
    Mitsikostas, Dimos-Dimitrios
    Ohsfeldt, Robert L.
    Vozikis, Athanassios
    Koufopoulou, Paraskevi
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 979 - 990
  • [2] Cost-effectiveness analysis of erenumab vs onabotulinumtoxinA for chronic migraine in Spain
    Pozo-Rosich, Patricia
    Poveda, Jose Luis
    Sanchez, Sergio
    Crespo, Carlos
    Martinez, Maria
    Irimia, Pablo
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 118 - 119
  • [3] COST-EFFECTIVENESS ANALYSIS OF ERENUMAB VERSUS TOPIRAMATE FOR PATIENTS WITH CHRONIC MIGRAINES TO IDENTIFY THE COST-EFFECTIVE PRICE THRESHOLD IN GREECE
    Giannouchos, T.
    Ohsfeldt, R. L.
    VALUE IN HEALTH, 2019, 22 : S277 - S277
  • [4] Cost-Effectiveness of Initial Prophylactic Treatment of Chronic Migraine: Oral Medications versus OnabotulinumtoxinA
    Kelley, Kristin
    Schoenbrunner, Anna
    Murphy, James
    NEUROLOGY, 2016, 86
  • [5] COST-EFFECTIVENESS OF ERENUMAB FOR THE PREVENTION OF MIGRAINE IN PORTUGAL
    Silva, C.
    Monge, S.
    Cooney, P.
    Mahon, R.
    Laires, P. A.
    VALUE IN HEALTH, 2020, 23 : S633 - S633
  • [6] COST-EFFECTIVENESS OF ONABOTULINUMTOXINA FOR PROPHYLAXIS OF HEADACHES IN ADULTS WITH CHRONIC MIGRAINE IN CANADA
    Bloudek, L. M.
    Hansen, R. N.
    Sanderson, J. C.
    Kan, L.
    Petrovic, G.
    Varon, S. F.
    Sullivan, S. D.
    VALUE IN HEALTH, 2013, 16 (03) : A105 - A105
  • [7] Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine
    Mahon, Ronan
    Vo, Pamela
    Pannagl, Katharina
    Tiwari, Santosh
    Heemstra, Harald
    Ferraris, Matias
    Zhao, Jing
    Betts, Keith A.
    Proot, Pascal
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (01) : 105 - 112
  • [8] Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
    Pozo-Rosich, Patricia
    Poveda, Jose Luis
    Crespo, Carlos
    Martinez, Maria
    Rodriguez, Jose Manuel
    Irimia, Pablo
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [9] Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
    Patricia Pozo-Rosich
    José Luis Poveda
    Carlos Crespo
    María Martínez
    José Manuel Rodríguez
    Pablo Irimia
    The Journal of Headache and Pain, 25
  • [10] Response to erenumab and onabotulinumtoxinA: comparative analysis in two cohorts of chronic migraine patients
    Torres-Ferrus, Marta
    Caronna, Edoardo
    Alpuente, Alicia
    Mas-de-les-Valls, Ruth
    Gine-Cipres, Eulalia
    Pozo-Rosich, Patricia
    CEPHALALGIA, 2023, 43 (1supp)
12345